tezosentan has been researched along with dobutamine in 2 studies
| Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (dobutamine) | Trials (dobutamine) | Recent Studies (post-2010) (dobutamine) |
|---|---|---|---|---|---|
| 157 | 29 | 33 | 6,357 | 818 | 1,011 |
| Protein | Taxonomy | tezosentan (IC50) | dobutamine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 4.17 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 5.551 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.519 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.975 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.517 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.383 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 1.944 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 0.599 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 2.966 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.383 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.114 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.895 | |
| D(3) dopamine receptor | Homo sapiens (human) | 4.985 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.155 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.518 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Durand, JB; Kobrin, I; Nagueh, S; Pratt, C; Torre-Amione, G; Vooletich, MT | 1 |
1 trial(s) available for tezosentan and dobutamine
| Article | Year |
|---|---|
A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure.
Topics: Acute Disease; Aged; Dobutamine; Double-Blind Method; Drug Tolerance; Echocardiography, Doppler; Endothelin Receptor Antagonists; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Pilot Projects; Pyridines; Safety; Tetrazoles | 2001 |
1 other study(ies) available for tezosentan and dobutamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |